nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-183-11-70-73nogr-1479Research ArticleОБЗОРREVIEWРоль саркопении в развитии неалкогольной жировой болезни печениThe role of sarcopenia in the development of non-alcoholic fatty liver diseasehttps://orcid.org/0000-0002-1095-8787ГриневичВ. Б.GrinevichV. B.

Гриневич Владимир Борисович, заведующий 2 кафедрой (терапии усовершенствования врачей), д. м. н., профессор

194044, Санкт-Петербург, улица Академика Лебедева, д. 6

Vladimir B. Grinevich, Head of 2nd Therapy department of postgraduate education, DSci, professor; Scopus Author ID: 7005167197

194044, St. Petersburg, Akademika Lebedev street, 6

https://orcid.org/0000-0002-8445-8363СасЕ. И.SasE. I.

Сас Евгений Иванович, д. м. н., профессор 2 кафедры (терапии усовершенствования врачей)

194044, Санкт-Петербург, улица Академика Лебедева, д. 6

Evgeny I. Sas, M.D., D. Sc. (Medicine), Professor of 2nd Therapy department of postgraduate education

194044, St. Petersburg, Akademika Lebedev street, 6

doctorsas@rambler.ruФГБВОУ ВО «Военно-медицинская академия имени С. М. Кирова» МО РФРоссияMilitary Medical Academy named after S. M. KirovRussian Federation202014112020183117073Copyright © Гриневич В.Б., Сас Е.И., 20202020Гриневич В.Б., Сас Е.И.Grinevich V.B., Sas E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1479

В настоящее время опубликовано большое количество исследований дополняющий наши знания по саркопении и ее влиянию на развитие метаболических нарушений, в том числе, на формирование НАЖБП. Это данные позволяют по новому посмотреть на фармакологические и нефармакологические подходы к терапии НЖБП, основываясь на базовых физиологических процессах, в том числе на биологической оси «мышцы — печень». Это дает убедительное обоснование для изучения скелетных мышц в качестве основной терапевтической мишени при НАЖБП и метаболическом синдроме.

Currently, a large number of studies have been published supplementing our knowledge of sarcopenia and its effect on the development of metabolic disorders, including the formation of NAFLD. This data allows a new look at the pharmacological and non-pharmacological approaches to the treatment of NAFLD, based on basic physiological processes, including the biological axis of the muscle — the liver. This provides a compelling rationale for studying skeletal muscle as the main therapeutic target for NAFLD and metabolic syndrome.

саркопенияНАЖБПметаболический синдромsarcopeniaNAFLDmetabolic syndromeReferencesWilliams C. D., Stengel J., Asike M. I. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011, no. 140, pp. 124–131.Williams C. D., Stengel J., Asike M. I. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011, no. 140, pp. 124–131.Bedogni G., Miglioli L., Masutti F. et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005. No.42, pp. 44–52Bedogni G., Miglioli L., Masutti F. et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005. No.42, pp. 44–52Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L. et al. Weight Loss via Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015. No. 42, pp. 44–52Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L. et al. Weight Loss via Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015. No. 42, pp. 44–52Hong H. C., Hwang S. Y., Choi H. Y. et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology. 2014; 59: 1772–1778.Hong H. C., Hwang S. Y., Choi H. Y. et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology. 2014; 59: 1772–1778.Lim S., Kim J. H., Yoon J. W. et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care. 2010. No. 33, pp. 1652–1654.Lim S., Kim J. H., Yoon J. W. et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care. 2010. No. 33, pp. 1652–1654.Kim T. N., Park M. S., Yang S. J. et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care. 2010; 33: 1497–1499.Kim T. N., Park M. S., Yang S. J. et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care. 2010; 33: 1497–1499.Lee Y. H., Jung K. S., Kim S. U. et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES2008–2011). J Hepatol. 2015; 63: 486–493.Lee Y. H., Jung K. S., Kim S. U. et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES2008–2011). J Hepatol. 2015; 63: 486–493.Kim S. W. Jung H. W. Which one is associated with nonalcoholic fatty liver disease? Small muscle mass or large fat mass. Hepatology. 2015; 61: 1764Kim S. W. Jung H. W. Which one is associated with nonalcoholic fatty liver disease? Small muscle mass or large fat mass. Hepatology. 2015; 61: 1764Issa D., Alkhouri N., Tsien C. et al. Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis. Hepatology. 2014; 60: 428–4299.Issa D., Alkhouri N., Tsien C. et al. Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis. Hepatology. 2014; 60: 428–4299.Bredella M. A., Ghomi R. H., Thomas B. J. et al. Comparison of DXA and CT in the assessment of body composition in premenopausal women with obesity and anorexia nervosa. Obesity (Silver Spring). 2010; 18: 2227–2233Bredella M. A., Ghomi R. H., Thomas B. J. et al. Comparison of DXA and CT in the assessment of body composition in premenopausal women with obesity and anorexia nervosa. Obesity (Silver Spring). 2010; 18: 2227–2233Giusto M., Lattanzi B., Albanese C., et al. Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry. Eur J Gastroenterol Hepatol. 2015; 27: 328–334.Giusto M., Lattanzi B., Albanese C., et al. Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry. Eur J Gastroenterol Hepatol. 2015; 27: 328–334.Henningsen J., Rigbolt K. T., Blagoev B., Pedersen B. K., Kratchmarova I. Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol Cell Proteomics. 2010; 9: 2482–2496.Henningsen J., Rigbolt K. T., Blagoev B., Pedersen B. K., Kratchmarova I. Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol Cell Proteomics. 2010; 9: 2482–2496.McPherron A.C., Guo T., Bond N. D., Gavrilova O. Increasing muscle mass to improve metabolism. Adipocyte. 2013; 2: 92–98.McPherron A.C., Guo T., Bond N. D., Gavrilova O. Increasing muscle mass to improve metabolism. Adipocyte. 2013; 2: 92–98.Dasarathy S. Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease? Hepatology. 2014; 60: 22–25.Dasarathy S. Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease? Hepatology. 2014; 60: 22–25.Bonala S., McFarlane C., Ang J. et al. Pid1 induces insulin resistance in both human and mouse skeletal muscle during obesity. Mol Endocrinol. 2013; 27: 1518–1535.Bonala S., McFarlane C., Ang J. et al. Pid1 induces insulin resistance in both human and mouse skeletal muscle during obesity. Mol Endocrinol. 2013; 27: 1518–1535.Zhang C., McFarlane C., Lokireddy S. et al. Myostatindeficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia. 2011; 54: 1491–1501.Zhang C., McFarlane C., Lokireddy S. et al. Myostatindeficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia. 2011; 54: 1491–1501.Dasarathy S, Muc S, Runkana A, Mullen KD, KaminskyRuss K, McCullough AJ. Alteration in body composition in the portacaval anastamosis rat is mediated by increased expression of myostatin. Am J Physiol Gastrointest Liver Physiol. 2011 Oct;301(4): G731–8. doi: 10.1152/ajpgi.00161.2011. Epub 2011 Jul 28. PMID: 21799182; PMCID: PMC3774342.Dasarathy S, Muc S, Runkana A, Mullen KD, KaminskyRuss K, McCullough AJ. Alteration in body composition in the portacaval anastamosis rat is mediated by increased expression of myostatin. Am J Physiol Gastrointest Liver Physiol. 2011 Oct;301(4): G731–8. doi: 10.1152/ajpgi.00161.2011. Epub 2011 Jul 28. PMID: 21799182; PMCID: PMC3774342.Seldin M. M., Peterson J. M., Byerly M. S., Wei Z., Wong G. W. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012; 287: 11968–11980.Seldin M. M., Peterson J. M., Byerly M. S., Wei Z., Wong G. W. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012; 287: 11968–11980.Polyzos S. A. Kountouras J., Anastasilakis A. D., Geladari E. V. Irisin in patients with nonalcoholic fatty liver disease. Metabolism. 2014; 63: 207–217Polyzos S. A. Kountouras J., Anastasilakis A. D., Geladari E. V. Irisin in patients with nonalcoholic fatty liver disease. Metabolism. 2014; 63: 207–217Glass C., Hipskind P., Tsien C., Malin S. K. et al. Sarcopenia and a physiologically low respiratory quotient in patients with cirrhosis: a prospective controlled study. J Appl Physiol. 1985; 2013: 559–565.Glass C., Hipskind P., Tsien C., Malin S. K. et al. Sarcopenia and a physiologically low respiratory quotient in patients with cirrhosis: a prospective controlled study. J Appl Physiol. 1985; 2013: 559–565.

The authors declare that there are no conflicts of interest present.